ArticleBreast cancer research and treatment2025
Axillary dissection is avoidable in most cT1N0 triple-negative & HER2+ breast cancers treated with upfront surgery.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe use of neoadjuvant chemotherapy (NAC) in cT1N0 patients with triple-negative (TN) or HER2-positive (HER2+) breast cancer has been controversial. It is unclear whether NAC or upfront surgery minimizes axillary dissection (ALND) risk in the contemporary cT1N0 TN/HER2+ patient population.
methodsConsecutive cT1N0 TN/HER2+ patients who received NAC or underwent upfront surgery at our institution between 01/2020-12/2022 were examined. ALND was indicated for any positive sentinel nodes (+SLNs) after NAC, ≥ 3 positive SLNs after upfront surgery, or 1-2 positive SLNs after upfront mastectomy not requiring radiotherapy (RT). Clinicopathologic features, nodal burden, and ALND rates were compared between NAC versus upfront surgery cohorts.
resultsAmong 506 patients, 43% (N = 218) were TN and 57% (N = 288) were HER2+; 9% (N = 47) received NAC before surgery; 68%( N = 343) underwent upfront breast-conserving surgery (BCS); 23% (N = 116) underwent upfront mastectomy. Axillary ultrasound was performed in 23% of patients who received NAC versus 26% of patients who underwent upfront BCS versus 33% of patients who underwent upfront mastectomy. ALND was performed in 6.4% (N = 3) of patients with any positive SLN after NAC, 1.7% (N = 6) who underwent upfront BCS, and 1.7% (N = 2) who underwent upfront mastectomy with ≥ 3 positive SLNs or 1-2 positive SLNs not meeting RT criteria (p = 0.13). No factors were associated with ALND, including T stage, upfront versus NAC approach, or tumor subtype.
conclusionNodal disease burden is low among cT1N0 TN/HER2+ patients even in the absence of routine axillary ultrasound. ALND was performed in < 2% of patients with cT1N0 TN/HER2+ disease who had upfront surgery, and adjuvant systemic therapy was de-escalated among many pathologically node-negative patients following surgery.
Indexed as
Identifiers
40719987What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.